Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback